SK pharmteco Announces CGMP Qualification of its Commercial-Scale Viral Vector Manufacturing Facility in France

RANCHO CORDOVA, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- SK pharmteco today announced the successful CGMP qualification of its manufacturing facility in Corbeil-Essonnes, France. This state-of-the-art plant is now fully operational and prepared to support late-stage and commercial viral vector programs at scale.

Recently, the facility was inspected by the ANSM (French Health Authority) and was successfully approved for operations. It has since produced its first batch using the company’s proprietary AAVelocity™ platform, a cornerstone of SK pharmteco’s extensive history in viral vector manufacturing.

“The qualification of this new facility marks a crucial milestone for SK pharmteco and our partners," said Joerg Ahlgrimm, CEO of SK pharmteco. "By providing a fully inspected and approved environment that mirrors our development workflows, we eliminate the traditional 'readiness gap.' Our clients can now scale from preclinical stages to commercial supply with the same teams, the same platforms, and the same systems, ensuring total continuity and faster speed-to-market."

Bridging the Gap from Clinical to Commercial
The new infrastructure is specifically designed for reproducibility and scale, offering:

• Two multiproduct and independent manufacturing facilities
• Two independent viral vector production suites
• 5,000 m² purpose-built CGMP facility designed for scalable viral vector manufacturing
• 12 single-use bioreactors from 50 L to 1,000 L providing a total installed upstream capacity of 5,000 L
• Capacity for up to 40 cGMP batches per year, supporting parallel processing and reliable supply
  
  

By leveraging its established platforms, AAVelocity^™ and LentiSure™, SK pharmteco ensures that processes running at a clinical scale remain reliable and steady when scaled up to larger commercial volumes, greatly reducing the risks for cell and gene therapy developers.

Additionally, the expansion directly addresses the critical pain points currently facing the viral vector market, including:

• Regulatory Confidence: After inspection and approval by health authorities, the facility meets the highest standards of CGMP compliance.
• Operational Continuity: Clients no longer need to switch CDMOs during scale-up, preventing delays, knowledge loss, and comparability risks related to tech transfers.

When combined with SK pharmteco’s other gene therapy manufacturing location outside of Philadelphia, this expansion enhances SK Pharmteco’s role as a leading global partner in viral vector manufacturing.

About SK pharmteco
SK pharmteco is a global contract development and manufacturing organization (CDMO) with production sites, research & development facilities, and analytical laboratories across the U.S., Europe, and South Korea. The company’s core capabilities center on small molecules, peptides, and viral vectors, providing the specialized expertise needed to bring complex therapies to market. Through these pillars, SK pharmteco supports biopharmaceutical partners of all sizes with comprehensive development and manufacturing solutions worldwide. SK pharmteco is a subsidiary of SK Inc. (SK), the strategic investment company for SK Group, South Korea’s second-largest conglomerate. 

Contact:
Keith Bowermaster, APR, CCMP
Communications Consultant
keith.bowermaster@skpt.com